Islamagic, Erna <br/><br/>
The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.  [electronic resource] 

 -  Clinical lymphoma, myeloma & leukemia  04 2017 
 - 238-240 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>2152-2669 
<br/><br/><label>Standard No.: </label>10.1016/j.clml.2017.02.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antineoplastic Agents--therapeutic use<br/>Bosnia and Herzegovina<br/>Drugs, Generic--therapeutic use<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Imatinib Mesylate--therapeutic use<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Retrospective Studies